EMEA-002448-PIP01-18-M02
Table of contents
Key facts
| Active substance |
PEGylated-fibroblast growth factor 21 (BMS-986036)
|
| Therapeutic area |
Gastroentology-Hepatology
|
| Decision number |
P/0346/2021
|
| PIP number |
EMEA-002448-PIP01-18-M02
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of non-alcoholic steatohepatitis (NASH)
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
Bristol-Myers Squibb International Corporation
Tel. +44 1895523740 |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|